Can a Triple-Drug rechallenge tame colorectal cancer?
NCT ID NCT06321081
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This phase 2 trial is investigating whether a combination of three drugs—irinotecan, cetuximab, and envafolimab—can control tumor growth when given again to people with metastatic colorectal cancer who had previously responded to similar treatments. The study enrolls adults whose cancer has a specific genetic profile (RAS/BRAF wild-type) and who have already benefited from irinotecan and cetuximab in earlier lines of therapy. Researchers are measuring how long the cancer stays under control and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of irinotecan, cetuximab, and envafolimab
- What this could lead to
- If successful, this rechallenge strategy could offer a new treatment option for patients with metastatic colorectal cancer whose disease has progressed after initial response to similar drugs.
- What could go wrong
- This is a small, early-phase trial with only 60 participants, so results may not apply broadly. The combination may cause significant side effects, and not all patients may benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- Can a new pill outsmart RAS-Mutant cancers?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?